Pure Extracts Technologies Past Earnings Performance
Past criteria checks 0/6
Pure Extracts Technologies has been growing earnings at an average annual rate of 37.9%, while the Pharmaceuticals industry saw earnings growing at 67.6% annually. Revenues have been growing at an average rate of 157.2% per year.
Key information
37.9%
Earnings growth rate
44.2%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | 157.2% |
Return on equity | n/a |
Net Margin | -163.8% |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pure Extracts Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 2 | -4 | 3 | 0 |
31 Dec 22 | 2 | -5 | 3 | 0 |
30 Sep 22 | 2 | -5 | 4 | 0 |
30 Jun 22 | 1 | -5 | 4 | 0 |
31 Mar 22 | 1 | -6 | 5 | 0 |
31 Dec 21 | 1 | -11 | 10 | 0 |
30 Sep 21 | 0 | -21 | 16 | 0 |
30 Jun 21 | 0 | -21 | 16 | 0 |
31 Mar 21 | 0 | -19 | 15 | 0 |
31 Dec 20 | 0 | -14 | 9 | 0 |
30 Sep 20 | 0 | -4 | 2 | 0 |
30 Jun 20 | 0 | -3 | 2 | 0 |
Quality Earnings: PULL is currently unprofitable.
Growing Profit Margin: PULL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PULL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare PULL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PULL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: PULL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.